BackAeglea BioTherapeutics Overview

Aeglea BioTherapeutics EBIT

EBIT (Earnings Before Interest and Taxes) analysis for AGLE.

Quarterly EBIT

-$45.64M
↑ 14.8% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$206.99M
↓ 142% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin